tirzepatide injections des moines Lilly launches lower-price weight-loss drug without injector pen Tirzepatide Flex-Dose 2 mL Injectable

Canadians show rising interest in GLP-1s, but misconceptions and access barriers persist A significant gap in understanding obesity as a chronic disease may be fuelling stigma and shaping the future of weight management benefits in Canada, according to new poll data from Phoenix, a digital health clinic for men

Our patients have been able to lose, on average, 16.9% of their body weight in just 68 weeks

Forgetting dose floors: The calculator always floors the number of doses per vial to avoid overestimating

Side effects are primarily gastrointestinal, including diarrhea, constipation, and abdominal discomfort, ironically similar to GLP-1 medications but much milder